异位ILT3控制B细胞慢性淋巴细胞白血病中BCR依赖性Akt活化
慢性淋巴细胞白血病(CLL)中长期无进展患者比例较高,提示存在抑制肿瘤B细胞增殖的调控网络。研究基于CLL细胞中信号适配蛋白p66Shc缺陷的发现,显示p66Shc缺失塑造CLL细胞转录谱并上调髓系细胞通常表达的表面受体ILT3。ILT3在CLL中的异位表达是肿瘤性B细胞和造血干细胞的独特特征,受Deltex1驱动,ILT3触发可抑制BCR刺激后的Akt活化,机制涉及ILT3、BCR与磷脂酰肌醇-3,4,5-三磷酸5-磷酸酶1在细胞表面形成抑制性簇。
要点
- p66Shc缺陷导致CLL细胞上调表面受体ILT3,ILT3是CLL恶性肿瘤的选择性标志。
- ILT3在CLL中的表达由Deltex1驱动,并代表成熟CLL细胞与骨髓祖细胞间的表型连续性。
- ILT3触发通过形成ILT3、BCR与磷脂酰肌醇-3,4,5-三磷酸5-磷酸酶1抑制性簇,抑制BCR刺激后的Akt活化。
核心结论
- ILT3是CLL中p66Shc缺陷的特征分子,可能通过抑制Akt通路在控制肿瘤进展的调控网络中发挥功能作用。
研究设计与样本
- 基于前期发现CLL细胞中信号适配蛋白p66Shc缺陷,识别该缺陷导致的独特表型特征。
主要发现
- p66Shc缺失塑造CLL细胞转录谱并导致表面受体ILT3上调。
- ILT3在CLL中的异位表达是肿瘤性B细胞和造血干细胞的独特特征,是CLL恶性肿瘤的选择性标志。
- ILT3在CLL中的表达由Deltex1驱动。
- ILT3触发抑制B细胞受体(BCR)刺激后的Akt激酶活化。
- 该效应通过ILT3、BCR与磷脂酰肌醇-3,4,5-三磷酸5-磷酸酶1在细胞表面动态聚集成抑制性簇实现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The high proportion of long-term nonprogressors among chronic lymphocytic leukemia (CLL) patients suggests the existence of a regulatory network that restrains the proliferation of tumor B cells. The identification of molecular determinants composing such network is hence fundamental for our understanding of CLL pathogenesis. Based on our previous finding establishing a deficiency in the signaling adaptor p66Shc in CLL cells, we undertook to identify unique phenotypic traits caused by this defect. Here we show that a lack of p66Shc shapes the transcriptional profile of CLL cells and leads to an upregulation of the surface receptor ILT3, the immunoglobulin-like transcript 3 that is normally found on myeloid cells. The ectopic expression of ILT3 in CLL was a distinctive feature of neoplastic B cells and hematopoietic stem cells, thus identifying ILT3 as a selective marker of malignancy in CLL and the first example of phenotypic continuity between mature CLL cells and their progenitors in the bone marrow. ILT3 expression in CLL was found to be driven by Deltex1, a suppressor of antigen receptor signaling in lymphocytes. Triggering of ILT3 inhibited the activation of Akt kinase upon B-cell receptor (BCR) stimulation. This effect was achieved through the dynamic coalescence of ILT3, BCRs, and phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 into inhibitory clusters at the cell surface. Collectively, our findings identify ILT3 as a signature molecule of p66Shc deficiency in CLL and indicate that ILT3 may functionally contribute to a regulatory network controlling tumor progression by suppressing the Akt pathway.
引用
- Zurli V, Wimmer G, Cattaneo F, et al. Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. Blood. 2017. PMID: 28931525. doi:10.1182/blood-2017-03-775858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。